LSTA

Lisata Therapeutics, Inc. (LSTA) | Rumor.io

Lisata Therapeutics

LSTA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,165

Bullish sentiment (50-day avg)42%

Price to earnings ratio-0.79

Market capitalization16.2M

Earnings per share-1.64

Dividend yield (TTM)—

Revenue (annual)170K

Net income (annual)-16.6M

Social

What share of all stock conversation is about LSTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 17

Lisata Therapeutics ($LSTA) has acquired Marea Therapeutics in a stock-for-stock merger deal, with Marea becoming a wholly owned subsidiary.
The acquisition was accompanied by a $225 million Series C private placement, which will fund the combined biotech company into 2028.
Existing Lisata holders will own approximately 2.4% of the combined company on an as-converted basis, with the deal valuing the company at around $590 million and implying a valuation of approximately $1.57 per share.

Generated by AI

Sentiment

Of the messages about LSTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% +2.94	72.49% -10.46
Bearish	—	—	50% -2.94	27.51% +10.46

Bullish· Jan 21

$LSTA has a strong long-term potential with its clinical pipeline and an $8 target, currently trading near $2-4.
The recent buyout news is a bullish catalyst, with potential for buyers to engage in tender arbitrage if the deal holds.
$LSTA's unique MOA for certepetide (iRGD peptide adjuvant) promotes intratumoral penetration and potentially increases the efficacy of standard of care, making it a promising asset.

Bearish· Sep 16

$LSTA is experiencing a significant decline in value, down 11.31% at $5.33 in the last 20 minutes.
The company's management is being criticized for their handling of recent news releases, which some believe was intentionally timed to facilitate short selling.
The stock's price is expected to continue to fall, with some predicting it will eventually reach penny stock status due to a perceived lack of investor interest.

Generated by AI

Topics

Of the messages about LSTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	69.62%
Technical Analysis	—	0%	0%	15.93%
Analysts	—	0%	0%	7.22%
Macro	—	0%	0%	5.42%
Controversies	—	0%	0%	1.31%
Earnings	—	0%	0%	0.49%

Announcements· Sep 17

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock merger, with Marea shareholders owning approximately 59.54% of the combined company.
The acquisition was accompanied by a $225 million private placement to fund the combined company's pipeline, with existing Lisata shareholders diluted to 2.39% of the combined company.
The combined company will focus on developing first-in-class, next-generation medicines for cardioendocrine diseases, led by Marea's late-stage clinical candidates, with topline data from Phase 2 trials expected in the fourth quarter of 2027.

Technical Analysis· Jan 20

$LSTA is forming a "W" pattern on the 10m chart, potentially indicating a significant price movement.
The stock's RSI needs to recover before it can continue its upward trend, and a breakout of a falling wedge has been confirmed with a price target of $5.
The 20+100 and 10+200 SMAs are about to cross, which could trigger a significant price reaction, potentially leading to a huge price movement.

Generated by AI

Community

Of the messages about LSTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	63.77%	36.27%
Newcomers	—	0%	36.23%	63.73%

Regulars· Sep 17

The acquisition of Marea Therapeutics by Lisata Therapeutics involves a stock-for-stock merger with a separate $225M PIPE at $1.4914/share, as converted, and will result in Marea becoming a wholly owned subsidiary.
The combined company, Lisata Therapeutics, will focus on developing first-in-class, next-generation medicines for cardioendocrine diseases, led by Marea's late-stage clinical candidates, including MAR001/005, an anti-ANGPTL4 monoclonal Ab program.
The deal includes a reverse merger with Marea, with Lisata issuing 1.8m shares, 211k Series C preferred shares, and 23k Series C options, and PIPE investors buying 151k Series C preferred shares, which would be 150.9m shares after conversion.

Newcomers· Sep 17

Lisata Therapeutics ($LSTA) acquires Marea Therapeutics in a reverse merger, with Marea holders owning ~60% of the combined company, effectively a dilution of existing Lisata shareholders to 2.4% on an as-converted basis.
The acquisition is concurrent with a $225 million private placement to fund the combined biotech into 2028, with Lisata's existing holders diluted to 2.39% of the combined company.
The combined company will advance Marea's next-gen cardioendocrine pipeline, and the deal is seen as bearish due to reverse mergers signaling weak public market access, with a market capitalization of $13.2 million and a diluted float of 7.13 million shares.

Generated by AI

Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an...

5d agoYahoo Finance

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic functionSOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-g

6d agoYahoo Finance Australia

Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?

7d agoYahoo Finance

Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio

Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

11d agotheglobeandmail.com

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

12d agoBenzinga

Lisata deal propels Marea’s drug pipeline to Wall Street

Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

12d agoYahoo Finance

Also Discussed

Investors talking about LSTA also mention

#	Name	Attention
1	IDEAYA Biosciences Inc.IDYA	0%0
2	CHRA - Charah Solutions, Inc.	——
3	Assembly Biosciences Inc.ASMB	0%new
4	SGMA - SigmaTron International, Inc.	——
5	SMI - VanEck HIP Sustainable Muni ETF	——
6	Atlanticus Holdings CorporationATLC	0%0
7	Bolt Biotherapeutics, Inc.BOLT	0%0
8	ALTR - Altair Engineering Inc.	——
9	Hepion Pharmaceuticals, Inc.HEPA	0%0
10	Scinai Immunotherapeutics Ltd. American Depositary SharesSCNI	0%new

Lisata Therapeutics, Inc.

Healthcare
Biotechnology

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is designed to activate a novel uptake pathway that may improve the delivery and penetration of anti-cancer drugs within solid tumors. Lisata Therapeutics’ current work centers on oncology programs that evaluate certepetide in combination with existing cancer regimens across several solid tumor settings. The company also maintains research efforts in other disease areas through its broader development pipeline. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics plays a role in the biopharmaceutical market by advancing treatment approaches intended to enhance how established therapies reach tumor tissue.

Website

Location

110 Allen Road

Basking Ridge, NJ, 07920

United States

Social

What share of all stock conversation is about LSTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 17

Lisata Therapeutics ($LSTA) has acquired Marea Therapeutics in a stock-for-stock merger deal, with Marea becoming a wholly owned subsidiary.
The acquisition was accompanied by a $225 million Series C private placement, which will fund the combined biotech company into 2028.
Existing Lisata holders will own approximately 2.4% of the combined company on an as-converted basis, with the deal valuing the company at around $590 million and implying a valuation of approximately $1.57 per share.

Generated by AI

Sentiment

Of the messages about LSTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% +2.94	72.49% -10.46
Bearish	—	—	50% -2.94	27.51% +10.46

Bullish· Jan 21

$LSTA has a strong long-term potential with its clinical pipeline and an $8 target, currently trading near $2-4.
The recent buyout news is a bullish catalyst, with potential for buyers to engage in tender arbitrage if the deal holds.
$LSTA's unique MOA for certepetide (iRGD peptide adjuvant) promotes intratumoral penetration and potentially increases the efficacy of standard of care, making it a promising asset.

Bearish· Sep 16

$LSTA is experiencing a significant decline in value, down 11.31% at $5.33 in the last 20 minutes.
The company's management is being criticized for their handling of recent news releases, which some believe was intentionally timed to facilitate short selling.
The stock's price is expected to continue to fall, with some predicting it will eventually reach penny stock status due to a perceived lack of investor interest.

Generated by AI

Topics

Of the messages about LSTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	69.62%
Technical Analysis	—	0%	0%	15.93%
Analysts	—	0%	0%	7.22%
Macro	—	0%	0%	5.42%
Controversies	—	0%	0%	1.31%
Earnings	—	0%	0%	0.49%

Announcements· Sep 17

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock merger, with Marea shareholders owning approximately 59.54% of the combined company.
The acquisition was accompanied by a $225 million private placement to fund the combined company's pipeline, with existing Lisata shareholders diluted to 2.39% of the combined company.
The combined company will focus on developing first-in-class, next-generation medicines for cardioendocrine diseases, led by Marea's late-stage clinical candidates, with topline data from Phase 2 trials expected in the fourth quarter of 2027.

Technical Analysis· Jan 20

$LSTA is forming a "W" pattern on the 10m chart, potentially indicating a significant price movement.
The stock's RSI needs to recover before it can continue its upward trend, and a breakout of a falling wedge has been confirmed with a price target of $5.
The 20+100 and 10+200 SMAs are about to cross, which could trigger a significant price reaction, potentially leading to a huge price movement.

Generated by AI

Community

Of the messages about LSTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	63.77%	36.27%
Newcomers	—	0%	36.23%	63.73%

Regulars· Sep 17

The acquisition of Marea Therapeutics by Lisata Therapeutics involves a stock-for-stock merger with a separate $225M PIPE at $1.4914/share, as converted, and will result in Marea becoming a wholly owned subsidiary.
The combined company, Lisata Therapeutics, will focus on developing first-in-class, next-generation medicines for cardioendocrine diseases, led by Marea's late-stage clinical candidates, including MAR001/005, an anti-ANGPTL4 monoclonal Ab program.
The deal includes a reverse merger with Marea, with Lisata issuing 1.8m shares, 211k Series C preferred shares, and 23k Series C options, and PIPE investors buying 151k Series C preferred shares, which would be 150.9m shares after conversion.

Newcomers· Sep 17

Lisata Therapeutics ($LSTA) acquires Marea Therapeutics in a reverse merger, with Marea holders owning ~60% of the combined company, effectively a dilution of existing Lisata shareholders to 2.4% on an as-converted basis.
The acquisition is concurrent with a $225 million private placement to fund the combined biotech into 2028, with Lisata's existing holders diluted to 2.39% of the combined company.
The combined company will advance Marea's next-gen cardioendocrine pipeline, and the deal is seen as bearish due to reverse mergers signaling weak public market access, with a market capitalization of $13.2 million and a diluted float of 7.13 million shares.

Generated by AI

Lisata Therapeutics

Social

Sep 17

Bullish· Jan 21

Bearish· Sep 16

Announcements· Sep 17

Technical Analysis· Jan 20

Regulars· Sep 17

Newcomers· Sep 17

Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?

Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Lisata deal propels Marea’s drug pipeline to Wall Street

Also Discussed

Lisata Therapeutics, Inc.

Company Information

Location

Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?

Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Lisata deal propels Marea’s drug pipeline to Wall Street

Also Discussed

Social

Sep 17

Bullish· Jan 21

Bearish· Sep 16

Announcements· Sep 17

Technical Analysis· Jan 20

Regulars· Sep 17

Newcomers· Sep 17